A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis
Research Grant
Administered By
Ophthalmology
Awarded By
Bristol-Myers Squibb Company
Start Date
November 2, 2015
End Date
September 20, 2017
Administered By
Ophthalmology
Awarded By
Bristol-Myers Squibb Company
Start Date
November 2, 2015
End Date
September 20, 2017